Department of Biomedical Sciences, University of Ulsan, College of Medicine, Ulsan, Korea; Bio-Medical Institute of Technology, University of Ulsan, College of Medicine, Ulsan, Korea; Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea
Auto-generated profile, based on publicly available information
Ji-Hye Kim
Department of Biomedical Sciences, University of Ulsan, College of Medicine, Ulsan, Korea; Bio-Medical Institute of Technology, University of Ulsan, College of Medicine, Ulsan, Korea; Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea
The high abundance of mitochondria and the expression of mitochondrial uncoupling protein 1 (UCP1) confer upon brown adipose tissue (BAT) the unique capacity to convert chemical energy into heat at the expense of ATP synthesis. It was long believed that BAT is present only in infants, and so, it was not considered as a potential therapeutic target for metabolic syndrome; however, the discovery of metabolically active BAT in adult humans has re-stimulated interest in the contributions of BAT metabolic regulation and dysfunction to health and disease. Here we demonstrate that brown adipocyte autophagy plays a critical role in the regulation BAT activity and systemic energy metabolism. Mice deficient in brown adipocyte autophagy due to BAT-specific deletion of Atg7—a gene essential for autophagosome generation—maintained higher mitochondrial content due to suppression of mitochondrial clearance and exhibited improved insulin sensitivity and energy metabolism. Autophagy was upregulated in BAT of older mice compared to younger mice, suggesting its involvement in the age-dependent decline of BAT activity and metabolic rate. These findings suggest that brown adipocyte autophagy plays a crucial role in metabolism and that targeting this pathway may be a potential therapeutic strategy for metabolic syndrome.
1 November 2019 in Journal of Investigative Dermatology
BCPAP, SW1736, C643, Cal62 control (C), dasatinib-resistant (DR), and dasatinib-resistant cells maintained in 2μM dasatinib in response to indicated concentrations of selumetinib (μM) for 72 hours. Growth was measured by Sulforhodamine B.
Tumor weights were measured upon euthanasia for both the Cal62 DasRes and Parental cell lines treated for 29 days with 1mg/kg QD trametinib. Data as means +/- SEM (n=8; student t-test; ***, P < 0.0005)